A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Results with Loxo-305 could justify Lilly’s acquisition of Loxo, but its inventor, the UK’s Redx, can just read ‘em and weep.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Arqule’s investors have done pretty nicely out of today’s buyout by Merck & Co, but might be wondering whether they could have done better still.
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Sunesis’s vecabrutinib has yet to put a patient into remission, so hope rests on higher dosing of this next-generation BTK inhibitor.